查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067683

內分泌檢測市場規模、佔有率和趨勢分析報告：按檢測類型、技術、最終用途、地區和細分市場預測（2026-2033 年）

Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type (Thyroid Stimulating Hormone (TSH) Test, Testosterone Test), By Technology (Immunoassay, Sensor Technology), By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

內分泌檢測市場概覽

全球內分泌檢測市場預計到 2025 年將達到 143.5 億美元，預計到 2033 年將達到 273.2 億美元，2026 年至 2033 年的複合年成長率為 8.48%。

受糖尿病、甲狀腺疾病、肥胖症、不孕症及其他需要定期診斷監測的荷爾蒙相關疾病日益普遍的推動，該市場正在經歷穩定成長。

內分泌檢測產業的成長進一步得益於自動化免疫檢測平台的日益普及、預防醫學意識的提高以及醫院、私人實驗室和門診診所中先進荷爾蒙檢測技術的整合。

全球內分泌檢測市場的成長主要受代謝和荷爾蒙相關疾病負擔日益加重的驅動，尤其是糖尿病、甲狀腺功能障礙、肥胖症、生殖功能障礙和腎上腺疾病。隨著這些疾病盛行率的上升，醫院、私人實驗室和門診診所的常規荷爾蒙監測顯著增加。隨著醫療保健系統越來越重視早期診斷和長期疾病管理，對甲狀腺刺激素(TSH)、胰島素、皮質醇、睪固酮和生殖激素的檢測需求持續成長。同時，生活方式的改變、人口老化、肥胖率上升以及壓力相關的內分泌疾病也在加速全球內分泌檢測的成長。內分泌檢測在生育治療和女性健康管理中的應用日益廣泛，進一步推動了對雌二醇、孕酮、黃體生成素 (LH)、卵泡刺激素 (FSH) 和催乳素等荷爾蒙檢測的需求，尤其是在預防醫學意識日益增強的都市區醫療保健系統中。

市場成長要素之一是糖尿病和肥胖症管理計畫的快速擴張，這持續推高了對胰島素和代謝激素檢測的需求。 GLP-1療法和肥胖症管理藥物的創新也提高了醫生對內分泌監測和代謝評估的興趣。年輕族群慢性疾病負擔的加重也推動了檢測頻率的增加。例如，英國國家醫療服務體系（NHS）在2024年6月報告稱，40歲以下糖尿病患者人數從2022年的173,166人增加到2023年的216,440人，凸顯了代謝性疾病負擔的加速加重以及由此導致的內分泌檢測需求的成長。同樣，諾和諾德公司於2024年3月獲得美國食品藥物管理局（FDA）批准，其藥物Wegovi（Semaglutide）可用於降低有心血管疾病史的肥胖或超重成年人發生重大心血管不利事件的風險。這進一步證實了內分泌相關代謝管理日益成長的臨床重要性。這些趨勢正在推動全球內分泌診斷實驗室對長期監測的需求不斷成長。

荷爾蒙檢測平台的技術進步也顯著推動了市場擴張。實驗室擴大採用高度自動化的免疫檢測系統和串聯式質譜質譜技術，以提高分析靈敏度、縮短檢測時間和處理能力。精準內分泌學和生殖診斷的興起，推動了對高特異性荷爾蒙檢測法的需求，以支持複雜的臨床決策。此外，已開發國家和開發中國家不孕症治療和懷孕延遲病例的增加，也促使醫療機構拓展其生殖內分泌檢測服務。作為其生殖內分泌檢測產品組合擴展的一部分，西門子醫療於2024年3月推出了抗穆氏管荷爾蒙（AMH）檢測，旨在幫助醫生在製定體外受精（IVF）治療方案時評估卵巢儲備。此類產品創新不斷增強私人實驗室和醫院診斷中心的先進內分泌檢測能力。

另一個關鍵的市場促進因素是互聯內分泌監測技術與基於生物標記的疾病管理解決方案的日益融合。儘管傳統的臨床檢測仍然是整個市場內分泌診斷的核心，但醫療服務提供者正擴大將連續代謝監測與檢查室內分泌評估相結合，以支持長期疾病管理。診斷設備製造商與糖尿病管理公司之間的策略合作正在加速內分泌相關護理路徑生態系統的擴展。此外，預計在整個預測期內，對激素監測技術和生物標記驅動的診斷技術的投資增加將推動不孕症、甲狀腺疾病和代謝檢測領域的創新。

目錄

第1章：內分泌檢測市場：調查方法與範圍

第2章：內分泌檢測市場：執行摘要

  • 市場概覽
  • 測試類型概述
  • 技術概覽
  • 按應用程式概覽
  • 競爭格局概述

第3章：內分泌檢測市場：變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場譜系展望
  • 市場動態
  • 市場動態分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTEL 分析
  • 管道分析

第4章：內分泌檢測市場：依檢測類型分類的估算與趨勢分析

  • 全球內分泌檢測市場：按檢測類型分類的概覽
  • 全球內分泌檢測市場：按檢測類型分類的波動分析
  • 全球內分泌檢測市場：依檢測類型和銷售收入分類
  • 甲狀腺刺激素（TSH）檢測
  • 胰島素測試
  • 睪酮檢測
  • 皮質醇測試
  • 人類絨毛膜促性腺激素分泌(hCG) 荷爾蒙檢測
  • 濾泡刺激素（FSH）檢測
  • 黃體激素(LH) 檢測
  • 雌二醇 (E2) 檢測
  • 孕酮測試
  • 催乳素試驗
  • 脫氫表雄酮硫酸酯（DHEAS）檢測
  • 其他

第5章：內分泌檢測市場：依技術分類的估算與趨勢分析

  • 全球內分泌檢測市場：依技術分類的儀錶板
  • 全球內分泌檢測市場：基於技術的波動分析
  • 全球內分泌檢測市場：依技術、按銷售額分類
  • 免疫檢測
  • 串聯式質譜質譜法
  • 單株和多株抗體技術
  • 臨床化學
  • 感測器技術
  • 其他

第6章：內分泌檢測市場：依最終用途分類的估算與趨勢分析

  • 全球內分泌檢測市場：依最終用途分類的概覽
  • 全球內分泌檢測市場：依最終用途分類的波動分析
  • 全球內分泌檢測市場：依最終用途和收入分類
  • 醫院
  • 私人考試機構
  • 門診部
  • 其他

第7章 內分泌檢測市場：區域估算與趨勢分析

  • 區域儀錶板
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • 主要公司市佔率分析（2025 年）
    • Abbott Laboratories
    • AB Sciex
    • Agilent Technologies Inc.
    • bioMerieux SA
    • Bio-Rad Laboratories Inc.
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd.
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics Incorporated
    • Ortho Clinical Diagnostics
Product Code: 978-1-68038-862-6

Endocrine Testing Market Summary

The global endocrine testing market size was estimated at USD 14.35 billion in 2025 and is projected to reach USD 27.32 billion by 2033, growing at a CAGR of 8.48% from 2026 to 2033. The market is experiencing steady growth driven by the increasing prevalence of diabetes, thyroid disorders, obesity, fertility-related conditions, and other hormone-associated diseases requiring routine diagnostic monitoring.

The endocrine testing industry's growth is further supported by rising adoption of automated immunoassay platforms, expanding preventive healthcare awareness, and the growing integration of advanced hormone-testing technologies across hospitals, commercial laboratories, and ambulatory care centers.

The growth of the global endocrine testing market is primarily driven by the rising burden of metabolic and hormone-related disorders, particularly diabetes, thyroid dysfunction, obesity, reproductive disorders, and adrenal abnormalities. The increasing prevalence of these conditions has significantly expanded routine hormone monitoring across hospitals, commercial laboratories, and ambulatory care settings. Thyroid stimulating hormone (TSH), insulin, cortisol, testosterone, and reproductive hormone tests are witnessing sustained demand as healthcare systems increasingly emphasize early diagnosis and long-term disease management. In parallel, changing lifestyle patterns, aging populations, obesity incidence, and stress-related endocrine disorders are accelerating testing volumes globally. The growing use of endocrine assays in fertility management and women's health has further strengthened demand for testing for estradiol, progesterone, LH, FSH, and prolactin, particularly in urban healthcare systems with rising preventive healthcare awareness.

A major growth catalyst for the market is the rapid expansion of diabetes and obesity management programs, which continue to increase demand for insulin and metabolic hormone testing. Pharmaceutical innovation in GLP-1 therapies and obesity management has also amplified physician focus on endocrine monitoring and metabolic assessment. The increasing chronic disease burden among younger populations also supports the higher testing frequency. For instance, in June 2024, the NHS reported that diabetes cases among individuals under 40 years of age increased from 173,166 in 2022 to 216,440 in 2023, highlighting the accelerating burden of metabolic disorders and the associated rise in endocrine testing requirements. Similarly, in March 2024, Novo Nordisk received FDA approval for Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease, reinforcing the expanding clinical importance of endocrine-linked metabolic management. Such developments are increasing long-term monitoring requirements across endocrine diagnostic laboratories globally.

Technological advancements in hormone testing platforms are also contributing significantly to market expansion. Laboratories are increasingly adopting highly automated immunoassay systems and tandem mass spectrometry technologies to improve analytical sensitivity, turnaround time, and testing throughput. The shift toward precision endocrinology and reproductive diagnostics has increased demand for highly specific hormone assays that support complex clinical decisions. In addition, healthcare providers are expanding reproductive endocrinology testing menus due to increasing infertility treatment volumes and delayed pregnancies in developed and developing markets. Siemens Healthineers launched its Anti-Mullerian Hormone (AMH) Assay in March 2024 as an expansion of its reproductive endocrinology testing portfolio, designed to assist physicians in evaluating ovarian reserve for IVF-related treatment decisions. Such product innovations continue to strengthen advanced endocrine testing capabilities across commercial laboratories and hospital diagnostic centers.

Another key market driver is the increasing integration of connected endocrine monitoring technologies and biomarker-based disease management solutions. While traditional laboratory testing remains central to endocrine diagnostics within the market scope, healthcare providers are increasingly integrating continuous metabolic monitoring with laboratory-based endocrine assessments to support long-term disease management. Strategic collaborations between diagnostics manufacturers and diabetes management companies are accelerating ecosystem expansion across endocrine-related care pathways. Furthermore, growing investment in hormone-monitoring technologies and biomarker-driven diagnostics is expected to support innovation across the fertility, thyroid, and metabolic testing segments over the forecast period.

Global Endocrine Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global endocrine testing market report based on test type, end-use, technology, and region:

  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Thyroid Stimulating Hormone (TSH) Test
  • Insulin Test
  • Testosterone Test
  • Cortisol Test
  • Human Chorionic Gonadotropin (hCG) Hormone Test
  • Follicle Stimulating Hormone (FSH) Test
  • Luteinizing Hormone (LH) Test
  • Estradiol (E2) Test
  • Progesterone Test
  • Prolactin Test
  • Dehydroepiandrosterone Sulfate (DHEAS) Test
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay
  • Tandem Mass Spectrometry
  • Monoclonal & Polyclonal Antibody Technologies
  • Clinical Chemistry
  • Sensor Technology
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital
  • Commercial Laboratory
  • Ambulatory Care Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Endocrine Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Endocrine Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type Snapshot
  • 2.3. Technology Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Endocrine Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising Prevalence of Hormonal and Metabolic Disorders
    • 3.4.2. Growing Adoption of Automated Immunoassay and Molecular Diagnostic Technologies
    • 3.4.3. Increasing Focus on Preventive Healthcare and Routine Health Screening
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Advanced Endocrine Diagnostic Technologies
    • 3.5.2. Regulatory and Standardization Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Endocrine Testing Market: Test Type Estimates & Trend Analysis

  • 4.1. Global Endocrine Testing Market: Test Type Dashboard
  • 4.2. Global Endocrine Testing Market: Test Type Movement Analysis
  • 4.3. Global Endocrine Testing Market By Test Type, Revenue
  • 4.4. Thyroid Stimulating Hormone (TSH) Test
    • 4.4.1. Thyroid Stimulating Hormone (TSH) Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Insulin Test
    • 4.5.1. Insulin Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Testosterone Test
    • 4.6.1. Testosterone Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Cortisol Test
    • 4.7.1. Cortisol Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 4.8.1. Human Chorionic Gonadotropin (hCG) Hormone Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.9. Follicle Stimulating Hormone (FSH) Test
    • 4.9.1. Follicle Stimulating Hormone (FSH) Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.10. Luteinizing Hormone (LH) Test
    • 4.10.1. Luteinizing Hormone (LH) Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.11. Estradiol (E2) Test
    • 4.11.1. Estradiol (E2) Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.12. Progesterone Test
    • 4.12.1. Progesterone Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.13. Prolactin Test
    • 4.13.1. Prolactin Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.14. Dehydroepiandrosterone Sulfate (DHEAS) Test
    • 4.14.1. Dehydroepiandrosterone Sulfate (DHEAS) Test market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.15. Others
    • 4.15.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Endocrine Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Global Endocrine Testing Market: End Use Dashboard
  • 5.2. Global Endocrine Testing Market: End Use Movement Analysis
  • 5.3. Global Endocrine Testing Market by End Use, Revenue
  • 5.4. Immunoassay
    • 5.4.1. Immunoassay market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Tandem Mass Spectrometry
    • 5.5.1. Tandem Mass Spectrometry market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Monoclonal & Polyclonal Antibody Technologies
    • 5.6.1. Monoclonal & Polyclonal Antibody Technologies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Clinical Chemistry
    • 5.7.1. Clinical Chemistry market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Sensor Technology
    • 5.8.1. Sensor Technology market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Endocrine Testing Market: End Use Estimates & Trend Analysis

  • 6.1. Global Endocrine Testing Market: Technology Dashboard
  • 6.2. Global Endocrine Testing Market: Technology Movement Analysis
  • 6.3. Global Endocrine Testing Market by Technology, Revenue
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Commercial Laboratories
    • 6.5.1. Commercial Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Ambulatory Care Centers
    • 6.6.1. Ambulatory Care Centers market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Endocrine Testing Market: Regional Estimates & Trend Analysis by End Use Test Type, Technology, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Abbott Laboratories
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. End Use benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AB Sciex
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. End Use benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Agilent Technologies Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. End Use benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. bioMerieux SA
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. End Use benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Bio-Rad Laboratories Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. End Use benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. DiaSorin S.p.A.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. End Use benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. F. Hoffmann-La Roche Ltd.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. End Use benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Laboratory Corporation of America Holdings
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. End Use benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Quest Diagnostics Incorporated
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. End Use benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Ortho Clinical Diagnostics
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. End Use benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Endocrine Testing Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 5 Global Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 6 Global Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 North America Endocrine Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 9 North America Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 10 North America Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 11 U.S. Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 14 Canada Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 16 Canada Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 17 Mexico Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 19 Mexico Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 20 Europe Endocrine Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 23 Europe Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 France Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 25 France Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 26 France Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 27 Germany Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 29 Germany Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 30 UK Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 31 UK Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 32 UK Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 Spain Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 34 Spain Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 35 Spain Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 36 Italy Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 37 Italy Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 38 Italy Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 39 Asia Pacific Endocrine Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 40 Asia Pacific Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 43 Japan Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 44 Japan Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Japan Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 46 China Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 47 China Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 China Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 49 India Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 50 India Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 51 India Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 52 South Korea Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 53 South Korea Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 South Korea Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 55 Australia Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 56 Australia Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 57 Australia Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 58 Latin America Endocrine Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 59 Latin America Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 60 Latin America Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Latin America Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 62 Brazil Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 63 Brazil Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Brazil Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 65 Argentina Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 66 Argentina Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Argentina Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 68 MEA Endocrine Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 69 MEA Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 70 MEA Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 MEA Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 72 South Africa Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 73 South Africa Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 South Africa Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 75 Saudi Arabia Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 76 Saudi Arabia Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Saudi Arabia Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 78 UAE Endocrine Testing Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 79 UAE Endocrine Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 UAE Endocrine Testing Market, By Technology, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Endocrine testing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Endocrine testing market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Endocrine testing market: Test Type movement analysis
  • Fig. 14 Endocrine testing market: Test Type outlook and key takeaways
  • Fig. 15 Thyroid Stimulating Hormone (TSH) Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Insulin Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Testosterone Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Cortisol Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Human Chorionic Gonadotropin (hCG) Hormone Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Follicle Stimulating Hormone (FSH) Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Luteinizing Hormone (LH) Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Estradiol (E2) Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Progesterone Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Prolactin Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Dehydroepiandrosterone Sulfate (DHEAS) Test market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Endocrine testing market: Technology type movement analysis
  • Fig. 28 Endocrine testing market: Technology type outlook and key takeaways
  • Fig. 29 Immunoassay market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Tandem Mass Spectrometry market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Monoclonal & Polyclonal Antibody Technologies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Clinical Chemistry market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Sensor Technology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Endocrine testing market: End Use movement analysis
  • Fig. 36 Endocrine testing market: End Use outlook and key takeaways
  • Fig. 37 Hospital market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Commercial Laboratory market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Ambulatory Care Centers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Global endocrine testing market: Regional movement analysis
  • Fig. 42 Global endocrine testing market: Regional outlook and key takeaways
  • Fig. 43 Global endocrine testing market share and leading players
  • Fig. 44 North America, by country
  • Fig. 45 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 U.S. key country dynamics
  • Fig. 47 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Canada key country dynamics
  • Fig. 49 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Mexico key country dynamics
  • Fig. 51 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 UK key country dynamics
  • Fig. 54 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Germany key country dynamics
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 France key country dynamics
  • Fig. 58 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Italy key country dynamics
  • Fig. 60 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Spain key country dynamics
  • Fig. 62 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Denmark key country dynamics
  • Fig. 64 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Sweden key country dynamics
  • Fig. 66 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Norway key country dynamics
  • Fig. 68 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 China key country dynamics
  • Fig. 71 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Japan key country dynamics
  • Fig. 73 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 India key country dynamics
  • Fig. 75 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Thailand key country dynamics
  • Fig. 81 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Brazil key country dynamics
  • Fig. 84 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Argentina key country dynamics
  • Fig. 86 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 South Africa key country dynamics
  • Fig. 89 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Saudi Arabia key country dynamics
  • Fig. 91 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 UAE key country dynamics
  • Fig. 93 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Kuwait key country dynamics
  • Fig. 95 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)